Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24815022 | 0.87 | NR1H2 (0.38) | NR1H2NR1H3CNR1CNR2MAP3K12 | |
| SCHEMBL25747181 | 0.87 | CNR1 (0.37) | NR1H2NR1H3CNR1CNR2TLR9 | |
| SCHEMBL24815006 | 0.86 | CNR1 (0.36) | NR1H2NR1H3CNR1CNR2MAP3K12 | |
| SCHEMBL24007693 | 0.86 | CNR1 (0.36) | NR1H2NR1H3CNR1CNR2MAP3K12 | |
| SCHEMBL24007689 | 0.81 | NR1H2 (0.37) | NR1H2NR1H3CNR1CNR2TLR8 | |
| SCHEMBL25745829 | 0.80 | CNR1 (0.37) | NR1H2NR1H3CNR1CNR2 | |
| SCHEMBL25745880 | 0.80 | CNR1 (0.37) | NR1H2NR1H3CNR1CNR2 | |
| SCHEMBL26012596 | 0.72 | CNR2 (0.42) | CNR1CNR2 | |
| SCHEMBL24007546 | 0.72 | CNR1 (0.37) | CNR1CNR2KCNH2 | |
| SCHEMBL24815021 | 0.72 | CNR1 (0.37) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | NR1H2 4625/4885NR1H3 4612/4885CNR1 4118/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | NR1H2 4625/4885NR1H3 4612/4885CNR1 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.